EV source | EV type | EV cargo | Mechanism | Function | Refs |
---|---|---|---|---|---|
OC cell lines | Exosome | miR-1246 | Via Cav1/p-gp/M2-type macrophage axis | Confer chemoresistance | Kanlikilicer P et al. |
OC cell lines | Exosome | miR-429 | Target CASR via NF-κB | Confer chemoresistance | Li T et al. |
OC cell lines | Exosome | miR-21-3p | Target NAV3 | Increase resistance to cisplatin | Pink RC et al. |
OC cell lines | Exosome | miR-21-5p | Target PDHA1 | Inhibit chemosensitivity | Zhuang L et al. |
OC cell lines | Exosome | pGSN | Interact with HIF1α | Enhance chemoresistance | Asare-Werehene M et al. |
OC cell lines | sEV | pGSN | Regulate GSH | Enhance chemoresistance | Asare-Werehene M et al. |
Macrophages | Exosome | miR-223 | Via PTEN-PI3K/AKT pathway | Elicit a chemoresistant phenotype | Zhu X et al. |
TAMs | EV | GATA3 | Up-regulate the CD24/Siglec-10 axis | Enhance chemoresistance | Chen C et al. |
CAFs | Exosome | miR-98-5p | Down-regulate CDKN1A | Promote cisplatin resistance | Guo H et al. |
OC cell lines | Exosome | miR497, TP | Use exosome-liposome hybrid nanoparticles | Overcome chemoresistance | Li L et al. |
Mature bovine milk | Exosome | Cisplatin | Evade the endosome trapping | Enhance delivery of cisplatin | Zhou G et al. |
MSCs | EV | miR-18a-5p | Target NACC1 and activate the AKT/mTOR pathway | Promote cisplatin sensitivity | Wang X et al. |
hUCMSCs | Exosome | miR-146a | Via LAMC2-mediated PI3K/Akt axis | Promote docetaxel and taxane sensitivity | Qiu L et al. |